KRAS and neoplasm: In previous work, treating orthotopic 3LL lung tumors with KRAS-G12C inhibitors only provided temporary tumor control, and combinations with anti–PD-1 or anti–PD-L1 and anti-LAG3 failed to give additional benefit (8).